Stockscreener 앱 받기
0.00
100.00%
-5.00
전일 마감가:
$5.00
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$266.14M
수익:
$44.12M
순이익/손실:
$-156.25M
주가수익비율:
0.00
EPS:
-3.07
순현금흐름:
$-154.61M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$5.30
2 Seventy Bio Inc Stock (TSVT) Company Profile
명칭
2 Seventy Bio Inc
전화
339-499-9300
주소
60 BINNEY STREET, CAMBRIDGE
TSVT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TSVT
2 Seventy Bio Inc
|
0.00 | 266.14M | 44.12M | -156.25M | -154.61M | -3.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
368.51 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.75 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.82 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
665.19 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
289.40 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
2 Seventy Bio Inc Stock (TSVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-06 | 다운그레이드 | Goldman | Neutral → Sell |
| 2024-01-31 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-01-31 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-10-30 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-10-12 | 개시 | Citigroup | Buy |
| 2023-09-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-09-12 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-07-28 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-10-31 | 개시 | Guggenheim | Buy |
| 2022-05-02 | 개시 | Goldman | Buy |
| 2022-02-10 | 개시 | SVB Leerink | Outperform |
| 2022-01-06 | 개시 | Cowen | Outperform |
| 2021-11-09 | 개시 | Canaccord Genuity | Buy |
| 2021-11-08 | 개시 | Morgan Stanley | Overweight |
| 2021-11-08 | 개시 | Wedbush | Outperform |
모두보기
2 Seventy Bio Inc 주식(TSVT)의 최신 뉴스
Is now a turning point for 2seventy bio Inc.Free Real Trader Watchlist of Hot Stocks - Newser
Real time pattern detection on 2seventy bio Inc. stockLow Risk Stock Selection Strategy Guide - Newser
Analyzing net buyer seller activity in 2seventy bio Inc.Scalable Strategy with Chart Confirmation - Newser
How 2seventy bio Inc. stock performs during market volatilityControlled Entry Strategy With Safety Analytics - Newser
Long term hold vs stop loss in 2seventy bio Inc.Free Safe Entry Stock Watch Suggestions - Newser
Momentum divergence signals in 2seventy bio Inc. chartFree Weekly Hot Picks With Buy Confidence - Newser
Live Scanner Shows Breakout on 2seventy bio Inc.Watchlist for Smart Swing Trading Updated - metal.it
Traders Consider Averaging Down in 2seventy bio Inc.Exit Ready Momentum Stock Watchlist Expanded - beatles.ru
What drives 2seventy bio Inc. stock priceAchieve rapid portfolio growth with expert guidance - Jammu Links News
How does 2seventy bio Inc. compare to its industry peersFree Stock Market Forecast Reports - Jammu Links News
2seventy bio Inc. Stock Analysis and ForecastConsistent double returns - Jammu Links News
What are the technical indicators suggesting about 2seventy bio Inc.Achieve rapid financial growth with expert help - Jammu Links News
What are analysts’ price targets for 2seventy bio Inc. in the next 12 monthsDiscover breakthrough trading strategies - Jammu Links News
How many analysts rate 2seventy bio Inc. as a “Buy”Explosive portfolio gains - Jammu Links News
Should I hold or sell 2seventy bio Inc. stock in 2025Superior trading gains - Jammu Links News
How does 2seventy bio Inc. generate profit in a changing economyCapitalize on market momentum for maximum gains - Jammu Links News
What is the dividend policy of 2seventy bio Inc. stockCapitalize on fast-growing investment opportunities - Jammu Links News
What makes 2seventy bio Inc. stock price move sharplyConsistently superior profits - Jammu Links News
Is 2seventy bio Inc. stock overvalued or undervaluedHigh-profit stock alerts - Jammu Links News
Why is 2seventy bio Inc. stock attracting strong analyst attentionUnbelievable profit margins - Jammu Links News
What are the latest earnings results for 2seventy bio Inc.Get expert insights on market-moving stocks - Jammu Links News
When is 2seventy bio Inc. stock expected to show significant growthSpectacular growth rates - Jammu Links News
Is 2seventy bio Inc. Stock a Good Fit for Conservative InvestorsBuy Alerts With Low Risk Confirmation Noted - metal.it
Is 2seventy bio Inc. forming a reversal patternTechnical Stock Breakout Predictions Signal Entry Points - metal.it
Momentum Screeners Rank 2seventy bio Inc. in Top 5 TodayAlpha Driven Watchlist With Alerts Published - metal.it
Heatmap Data Shows High Activity in 2seventy bio Inc. SectorReal Time Alerts Based on AI Prediction Triggered - metal.it
Sector Leaders Rotate Capital Into 2seventy bio Inc.Breakout Confirmation With Entry Tracker Enabled - metal.it
2seventy bio Inc. Company’s Quarterly Earnings Growth: What the Numbers SayAI Powered Stock Call - metal.it
What catalysts could drive 2seventy bio Inc. stock higher in 2025Track emerging stocks with high growth potential - Jammu Links News
How strong is 2seventy bio Inc. company’s balance sheetAchieve consistent double-digit growth - Jammu Links News
Published on: 2025-07-27 15:37:28 - Jammu Links News
Can 2seventy bio Inc. stock recover from recent declineExplosive earning power - Jammu Links News
Why 2seventy bio Inc. stock attracts strong analyst attentionTop Performing Stocks - beatles.ru
Is 2seventy bio Inc. a good long term investmentDynamic investment growth - Jammu Links News
Krystal Biotech doses first patient in EMERALD-1 phase 1/2 trial for neurotrophic keratitis - Ophthalmology Times
FDA Accepts NDA for Zoliflodacin, Potentially First Gonorrhea Antibiotic in Decades - Managed Healthcare Executive
Cigna Launches AI Tools to Simplify Health Insurance, Improve Customer Experience - Managed Healthcare Executive
FDA Approves Ibtrozi For Adults With ROS1+ NSCLC - Managed Healthcare Executive
Alachua bio-manufacturing plant to lay off employees ahead of shutdown - WCJB | TV20
'Life is too short to work on things that are mediocre': Why this biotech CEO's 2nd drug approval is a big deal - The Business Journals
Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1+ NSCLC - Pharmacy Times
Bonnie Hui-Callahan, Pharm.D., Video Interview | 2025 MHE Emerging Leaders in Healthcare - Managed Healthcare Executive
Wellington Management Group LLP Reduces Stock Position in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
BNP Paribas Financial Markets Makes New Investment in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Deutsche Bank AG Has $1.10 Million Stock Position in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
MHE Week in Review –Medicaid Bill Mayhem, UnitedHealth’s Stock Plummets and More - Managed Healthcare Executive
Raymond James Financial Inc. Makes New $52,000 Investment in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
2Seventy Bio Reports Strong Q1 2025 Earnings - TipRanks
Investor relations - Bristol Myers Squibb
Wells Fargo & Company MN Has $96,000 Stake in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
2seventy bio completes merger with Bristol-Myers Squibb - Investing.com
2 Seventy Bio Inc (TSVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
1.48%
자본화:
|
볼륨(24시간):